Nurix Therapeutics Inc logo

Nurix Therapeutics Inc share price today

(NRIX)

Nurix Therapeutics Inc share price is $20.89 & ₹1,769.07

$20.89

▲

-0.6

(-2.79%)

Market is closed - opens 8 PM, 04 Dec 2024

View live Nurix Therapeutics Inc share price in Dollar and Rupees. Guide to invest in Nurix Therapeutics Inc from India. Also see the sentimental analysis on Indian investors investing in Nurix Therapeutics Inc. Get details on the Indian mutual funds that are investing in Nurix Therapeutics Inc. Get Analyst recommendations and forecasts along with all the Nurix Therapeutics Inc's financials.

Nurix Therapeutics Inc share price movements

  • $20.59
    $21.54

    Day's Volatility :4.41%

  • $6.58
    $29.56

    52 Weeks Volatility :77.74%

Nurix Therapeutics Inc Returns

PeriodNurix Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-12.96%
-6.2%
0.0%
6 Months
27.46%
1.7%
0.0%
1 Year
178.73%
11.6%
0.0%
3 Years
-22.59%
12.9%
-18.1%

Nurix Therapeutics Inc Key Statistics

in dollars & INR

Market Capitalization
$1.6B
Revenue TTM
$56.4M
EBITDA
$-186.4M
Earnings Per Share (EPS)
$-2.9
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-57.96%

How to invest in Nurix Therapeutics Inc from India?

It is very easy for Indian residents to invest directly in Nurix Therapeutics Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Nurix Therapeutics Inc stock in both rupees (INR) and dollars (USD). Search for Nurix Therapeutics Inc or NRIX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Nurix Therapeutics Inc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Nurix Therapeutics Inc shares which would translate to 0.041 fractional shares of Nurix Therapeutics Inc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Nurix Therapeutics Inc

-27%

Period: Sep 4, 2024 to Dec 3, 2024. Change in 30 Days versus previous period

Search volume for Nurix Therapeutics Inc on INDmoney from India has reduced in the last 30 days as on Dec 4, 2024. -27% less investors are searching Nurix Therapeutics Inc in the last 30 days versus the previous period.

Global Institutional Holdings in Nurix Therapeutics Inc

  • BlackRock Inc

    9.63%

  • Redmile Group, LLC

    6.04%

  • Vanguard Group Inc

    5.66%

  • Baker Bros Advisors LP

    5.48%

  • Deep Track Capital, LP

    5.46%

  • Wellington Management Company LLP

    4.92%

Analyst Recommendation on Nurix Therapeutics Inc

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Nurix Therapeutics Inc(by analysts ranked 0 to 5 stars)

Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
16
Hold
2
2
2
Sell
0
0
0

Analyst Forecast on Nurix Therapeutics Inc

What analysts predicted

Upside of 49.35%

Current:

$20.89

Target:

$31.20

Insights on Nurix Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 12.09M → 12.58M (in $), with an average increase of 3.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -41.51M → -48.95M (in $), with an average decrease of 8.6% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.6% return, outperforming this stock by 68.1%

Nurix Therapeutics Inc Financials in INR & Dollars

FY18Y/Y Change
Revenue
$37.4M
-
Net Income
$-9.4M
-
Net Profit Margin
-25.18%
-
FY19Y/Y Change
Revenue
$31.1M
↓ 16.91%
Net Income
$-21.7M
↑ 130.15%
Net Profit Margin
-69.74%
↓ 44.56%
FY20Y/Y Change
Revenue
$17.8M
↓ 42.73%
Net Income
$-43.2M
↑ 99.28%
Net Profit Margin
-242.66%
↓ 172.92%
FY21Y/Y Change
Revenue
$29.8M
↑ 66.95%
Net Income
$-117.2M
↑ 171.02%
Net Profit Margin
-393.93%
↓ 151.27%
FY22Y/Y Change
Revenue
$38.6M
↑ 29.84%
Net Income
$-166.0M
↑ 41.68%
Net Profit Margin
-429.87%
↓ 35.94%
FY23Y/Y Change
Revenue
$77.0M
↑ 99.31%
Net Income
$-143.9M
↓ 13.31%
Net Profit Margin
-186.98%
↑ 242.89%
Q2 FY23Q/Q Change
Revenue
$30.7M
↑ 141.83%
Net Income
$-21.8M
↓ 38.33%
Net Profit Margin
-71.03%
↑ 207.52%
Q3 FY23Q/Q Change
Revenue
$18.5M
↓ 39.8%
Net Income
$-37.0M
↑ 69.73%
Net Profit Margin
-200.26%
↓ 129.23%
Q4 FY23Q/Q Change
Revenue
$15.2M
↓ 17.91%
Net Income
$-42.0M
↑ 13.45%
Net Profit Margin
-276.77%
↓ 76.51%
Q1 FY24Q/Q Change
Revenue
$16.6M
↑ 9.41%
Net Income
$-41.5M
↓ 1.04%
Net Profit Margin
-250.33%
↑ 26.44%
Q2 FY24Q/Q Change
Revenue
$12.1M
↓ 27.09%
Net Income
$-44.5M
↑ 7.29%
Net Profit Margin
-368.39%
↓ 118.06%
Q3 FY24Q/Q Change
Revenue
$12.6M
↑ 4.1%
Net Income
$-49.0M
↑ 9.9%
Net Profit Margin
-388.91%
↓ 20.52%
FY18Y/Y Change
Total Assets
$45.4M
-
Total Liabilities
$82.2M
-
FY19Y/Y Change
Total Assets
$44.0M
↓ 2.97%
Total Liabilities
$101.8M
↑ 23.73%
FY20Y/Y Change
Total Assets
$396.3M
↑ 799.8%
Total Liabilities
$106.1M
↑ 4.24%
FY21Y/Y Change
Total Assets
$476.8M
↑ 20.29%
Total Liabilities
$134.5M
↑ 26.77%
FY22Y/Y Change
Total Assets
$416.8M
↓ 12.59%
Total Liabilities
$113.1M
↓ 15.92%
FY23Y/Y Change
Total Assets
$355.6M
↓ 14.68%
Total Liabilities
$155.1M
↑ 37.18%
Q2 FY23Q/Q Change
Total Assets
$350.6M
↓ 5.28%
Total Liabilities
$90.7M
↓ 5.62%
Q3 FY23Q/Q Change
Total Assets
$308.2M
↓ 12.1%
Total Liabilities
$74.4M
↓ 18.0%
Q4 FY23Q/Q Change
Total Assets
$364.5M
↑ 18.28%
Total Liabilities
$164.0M
↑ 120.56%
Q1 FY24Q/Q Change
Total Assets
$312.7M
↓ 14.23%
Total Liabilities
$143.9M
↓ 12.26%
Q2 FY24Q/Q Change
Total Assets
$511.0M
↑ 63.44%
Total Liabilities
$140.3M
↓ 2.49%
Q3 FY24Q/Q Change
Total Assets
$513.6M
↑ 0.5%
Total Liabilities
$136.7M
↓ 2.56%
FY18Y/Y Change
Operating Cash Flow
$-31.7M
-
Investing Cash Flow
$40.0M
-
Financing Cash Flow
$529.0K
-
FY19Y/Y Change
Operating Cash Flow
$601.0K
↓ 101.9%
Investing Cash Flow
$8.5M
↓ 78.75%
Financing Cash Flow
$126.0K
↓ 76.18%
FY20Y/Y Change
Operating Cash Flow
$-80.0K
↓ 113.31%
Investing Cash Flow
$-254.4M
↓ 3093.69%
Financing Cash Flow
$339.0M
↑ 268966.67%
FY21Y/Y Change
Operating Cash Flow
$-84.4M
↑ 105356.25%
Investing Cash Flow
$-108.3M
↓ 57.45%
Financing Cash Flow
$153.9M
↓ 54.61%
FY22Y/Y Change
Operating Cash Flow
$-159.8M
↑ 89.42%
Investing Cash Flow
$27.2M
↓ 125.12%
Financing Cash Flow
$117.2M
↓ 23.84%
Q2 FY23Q/Q Change
Operating Cash Flow
$-18.5M
↓ 61.88%
Investing Cash Flow
$43.8M
↑ 0.0%
Financing Cash Flow
$25.0K
↓ 98.31%
Q3 FY23Q/Q Change
Operating Cash Flow
$-41.1M
↑ 122.71%
Investing Cash Flow
$22.8M
↓ 48.04%
Financing Cash Flow
$1.7M
↑ 6716.0%

Nurix Therapeutics Inc Technicals Summary

Sell

Neutral

Buy

Nurix Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Nurix Therapeutics Inc Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nurix Therapeutics Inc
Nurix Therapeutics Inc
-14.18%
27.46%
178.73%
-22.59%
13.05%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.02%
-24.21%
-7.13%
21.97%
104.79%
Biontech Se
Biontech Se
7.55%
14.34%
18.7%
-58.12%
380.92%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-6.28%
66.39%
48.51%
42.94%
104.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.5%
-3.58%
31.51%
127.12%
108.61%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nurix Therapeutics Inc
Nurix Therapeutics Inc
NA
NA
NA
-2.77
-0.58
-0.29
NA
5.62
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.55
18.55
1.12
44.92
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.23
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nurix Therapeutics Inc
Nurix Therapeutics Inc
Buy
$1.6B
13.05%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.0B
104.79%
18.55
33.61%
Biontech Se
Biontech Se
Buy
$28.9B
380.92%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.7B
104.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
108.61%
32.84
-4.51%

About Nurix Therapeutics Inc

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe
Organization
Nurix Therapeutics Inc
Employees
284
CEO
Dr. Arthur T. Sands M.D., Ph.D.
Industry
Health Technology

Important FAQs about investing in Nurix Therapeutics Inc from India :

What is Nurix Therapeutics Inc share price today?

Nurix Therapeutics Inc (NRIX) share price today is $20.89.

Can Indians buy Nurix Therapeutics Inc shares?

Yes, Indians can invest in the Nurix Therapeutics Inc (NRIX) from India.

With INDmoney, you can buy Nurix Therapeutics Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Nurix Therapeutics Inc at zero transaction cost.

How can I buy Nurix Therapeutics Inc shares from India?

It is very easy to buy Nurix Therapeutics Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nurix Therapeutics Inc be purchased?

Yes, you can buy fractional shares of Nurix Therapeutics Inc with INDmoney app.

What are the documents required to start investing in Nurix Therapeutics Inc stocks?

To start investing in Nurix Therapeutics Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Nurix Therapeutics Inc

Today’s highest price of Nurix Therapeutics Inc (NRIX) is $21.54.

Today’s lowest price of Nurix Therapeutics Inc (NRIX) is $20.59.

What is today's market capitalisation of Nurix Therapeutics Inc

Today's market capitalisation of Nurix Therapeutics Inc NRIX is 1.6B

What is the 52 Week High and Low Range of Nurix Therapeutics Inc

  • 52 Week High

    $29.56

  • 52 Week Low

    $6.58

How much percentage Nurix Therapeutics Inc is down from its 52 Week High?

Nurix Therapeutics Inc (NRIX) share price is $20.89. It is down by 99% from its 52 Week High price of $29.56.

How much percentage Nurix Therapeutics Inc is up from its 52 Week low?

Nurix Therapeutics Inc (NRIX) share price is $20.89. It is up by 1% from its 52 Week Low price of $6.58.

What are the historical returns of Nurix Therapeutics Inc?

  • 1 Month Returns

    -14.18%

  • 3 Months Returns

    27.46%

  • 1 Year Returns

    178.73%

  • 5 Years Returns

    13.05%

Who is the Chief Executive Officer (CEO) of Nurix Therapeutics Inc

Dr. Arthur T. Sands M.D., Ph.D. is the current Chief Executive Officer (CEO) of Nurix Therapeutics Inc.